• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

byDavid XiangandHarsh Shah
March 29, 2022
in Chronic Disease, Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients with HER2-positive metastatic breast cancer.

2. Trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Approximately 20% of breast cancers express HER2, and although there are HER2-targeted therapies, they are not curative and most patients will have disease progression. The current standard treatment for HER2-positive metastatic breast cancer that progresses after trastuzumab with a taxane is trastuzumab emtansine. However, trastuzumab deruxtecan has been proposed to have durable antitumor activity. There is a gap in knowledge as to understanding the efficacy of trastuzumab deruxtecan compared to currently available HER2-directed regimens such as trastuzumab emtansine. This study found that trastuzumab deruxtecan is associated with an increased reduction in risk of disease progression or death in patients with HER2-positive metastatic breast cancer. This study was limited by factors such as including patients from countries in which trastuzumab emtansine was not yet readily available. Nevertheless, this study’s findings are significant, as they demonstrate that trastuzumab deruxtecan is superior to trastuzumab emtansine in reducing the risk of progression or death in HER2-positive metastatic breast cancer.

Click to read the study in NEJM

Relevant Reading: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

In-Depth [randomized control trial]: This multicenter, open-label randomized control trial studied 524 patients. Patients who had HER2-positive unresectable or metastatic breast cancer that had progressed during or after treatment with trastuzumab and a taxane were eligible for the study. Patients with brain metastases that were symptomatic or required treatment or had previously been treated with trastuzumab emtansine were excluded from the study. The primary outcome measure was progression-free survival. Outcomes in the primary analysis were assessed via a stratified log-rank test and analysis of progression-free survival. Based on the analysis, 75.8% of patients on trastuzumab deruxtecan had no disease progression at 12 months (95% confidence interval [ CI], 69.8 to 80.7) compared to 34.1% of patients on trastuzumab emtansine (95% CI, 27.7 to 40.5). 94.1% of patients on trastuzumab deruxtecan were alive at 12 months (95% CI, 90.3 to 96.4) while 85.9% of patients on trastuzumab emtansine were alive at 12 months (95% CI, 80.9 to 89.7). Overall response in these patients was 79.7% (95% CI, 74.3 to 84.4) for trastuzumab deruxtecan and 34.2% (95% CI, 28.5 to 40.3) for trastuzumab emtansine. Drug-related interstitial lung disease or pneumonitis occurred in 10% of patients receiving trastuzumab deruxtecan and in 1.9% of patients receiving trastuzumab emtansine. The incidence of a drug-related adverse event was 98.1% with trastuzumab deruxtecan and 86.6% with trastuzumab emtansine. Overall, this study demonstrated that trastuzumab deruxtecan is superior to trastuzumab emtansine in reducing the risk of progression or death in HER2-positive metastatic breast cancer patients, and is an effective new treatment for these patients.

RELATED REPORTS

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: HER2-negative breast cancermetastatic breast cancertrastuzumabtrastuzumab deruxtecantrastuzumab emtansine
Previous Post

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

Next Post

Large vessel occlusion stroke is associated with poor prognosis in children

RelatedReports

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
StudyGraphics

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

October 11, 2022
Age and number of islet autoantibodies associated with diabetes risk
Oncology

Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.

September 5, 2022
#VisualAbstract: Capivasertib in addition to fulvestrant improves  progression-free survival in ER⁺ advanced breast cancer
StudyGraphics

#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer

August 16, 2022
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
StudyGraphics

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

August 2, 2022
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Large vessel occlusion stroke is associated with poor prognosis in children

30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options